Breast Cancer Clinical Trial
Official title:
Novel Individualized Intervention for Behavioral Change Among High-Risk Group Cancer Survivors : Physical Activities by Technology Help (PATH)
PATH is a research study for cancer survivors to help participants to become more active. Studies suggested an association between inactivity and cancer. The investigators created new novel ways and technologies that may help participants to become more active. The three methods the investigators are studying are: 1) participant become active on her/his own; educational material will be provided; 2) working with a programmed health coach over the phone via text messages; and 3) using digital voice assist to help participant become more active. The digital voice assist will be delivered via Amazon Alexa on Echo speaker (it is the famous intelligent voice that you see in superball commercial by Alec Baldwin). This study is funded by the State of Maryland.
If the participant agree to be in this study, the investigators will ask the participant to
do the following things:
The participant will be asked questions about his/her physical activity (walking, running or
other exercise) to determine if he/she are eligible to participate. If the participant is
eligible and interested in participating, the investigators will ask hi/her to read and sign
the consent form.
After that, the investigators will randomly assign the participant to a research group (this
method would be similar to drawing numbers from a hat). The result will determine which group
the participant will belong to. The study would have three different groups:
1. Group one will be self-motivated to be physically active (control group)
2. The second group will receive smart daily text messages only (text group);
3. The last group would have the Amazon Echo smart device installed in participants' homes
and they will interact with a digital voice assist that will help them be active (Alexa
group).
- All study participants will receive a Fitbit device which you can keep after the
study.
- When the investigators start the study, the participant will be asked to start
wearing wrist device immediately. For the next one week the investigators will
monitor the participant daily number of steps to establish how active he/she is.
The participant will not be required to change his/her daily routine in the first
week.
- After the end of the first week, the investigators will ask the participant to
increase his/her daily steps to at least 10 thousand steps per day for the next
four weeks. In total the participant will have one week of hi/her normal daily
routine and four weeks of trying to do 10 thousand steps per day or more.
- If the participant is in the control group, the investigators will ask you to try
to do 10 thousand steps per day on his/her own.
- If the participant are in the text group, he/she will get smart text messages with
healthy tips to help track his/her activities and reach his/her daily goal.
- If the participant is in Alexa group, a study member will visit the participant at
his/her home before the end of the first week to install the Echo smart speaker and
to explain to the participant how to use the voice assist to help him/her become
more active for the next four weeks.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |